Cipla Gets Final Approval For Generic Version Of Epzicom Tablets

A global pharmaceutical company, Cipla Ltd., recently declared that it has received the final approval from United States Food and Drug Administration (USFDA) for Abbreviated New Drug Application (ANDA) for Abacavir and Lamivudine Tablets.

Cipla uses innovative technology and innovation to meet the day to day needs of all the patients.

Basically, Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug (RLD), Epzicom Tablets, 600 mg/300 mg of ViiV Healthcare Company and are recommended in combination with other antiretroviral agents for the treatment of HIV-1 infection.

As per reports, earlier, the Epzicom Tablets had US sales of around $346.3 million for the 12-month ending period in February 2017, and the product will now try to cover the whole US market, being commercially available shortly.

For Quick Trial – 8962000225 ✔
or mail us here:
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.